Insulin glulisine is a rapid-acting human insulin analogue produced by recombinant DNA technology using a non-pathogenic laboratory strain of Escherichia coli (K12). It differs from human insulin by the replacement of asparagine at position B3 with lysine and lysine at position B29 with glutamic acid. This modification results in a more rapid onset and shorter duration of action compared to regular human insulin, making it suitable for mealtime (prandial) glucose control in diabetes mellitus. It is typically administered subcutaneously just before (0-15 minutes) or soon after a meal.
Adult: Dosage is highly individualized based on metabolic needs, blood glucose monitoring, and glycemic control goals. Typically administered just before (0-15 min) or within 20 minutes after starting a meal. The total daily insulin requirement (TDD) is often between 0.5 to 1.0 IU/kg/day, with rapid-acting analogues like glulisine covering 50-70% of prandial needs. Dose adjustments are mandatory based on pre-meal blood glucose, carbohydrate intake, and planned physical activity.
Note: For subcutaneous use only. Administer in the abdominal wall, thigh, upper arm, or buttocks. Rotate injection sites within the same region to prevent lipodystrophy. Use a new needle for each injection. Do not administer intravenously or intramuscularly. If mixing with NPH insulin, draw insulin glulisine into the syringe first to prevent contamination of the vial.
Insulin glulisine binds to the insulin receptor on target cells (primarily liver, muscle, and adipose tissue), initiating a cascade of intracellular signaling events. This leads to the facilitated uptake of glucose from the bloodstream into cells, promotion of glycogen synthesis, inhibition of gluconeogenesis and glycogenolysis in the liver, and promotion of protein and lipid synthesis.
Pregnancy: Pregnancy Category B. Insulin is the drug of choice for glycemic control in pregnant women with diabetes (pre-existing or gestational). Insulin requirements may decrease in the first trimester and increase significantly during the second and third trimesters. Close monitoring of blood glucose is mandatory. Insulin glulisine can be used if clearly needed.
Driving: Patients must be aware that hypoglycemia can impair concentration and reaction time. Blood glucose should be checked before driving and regularly during long journeys. Always carry a fast-acting carbohydrate source.
| Corticosteroids (e.g., Prednisolone) | Antagonize insulin effect, leading to hyperglycemia and increased insulin requirement. | Major |
| Beta-blockers (e.g., Propranolol) | May mask tachycardia during hypoglycemia and may potentiate or weaken insulin's effect. | Moderate |
| Thiazolidinediones (e.g., Pioglitazone) | Can cause fluid retention, potentially worsening heart failure; monitor for edema and weight gain. | Moderate |
| Alcohol | Potentiates glucose-lowering effect, increasing risk of severe hypoglycemia, which can be prolonged. | Major |
| MAO Inhibitors, ACE Inhibitors | May increase hypoglycemic effect. | Moderate |
| Oral Hypoglycemics (Sulfonylureas, Meglitinides) | Additive hypoglycemic effect, risk of hypoglycemia. | Major |
| Thyroid hormones, Diuretics (Thiazides, Loop) | May increase blood glucose, requiring dose adjustment. | Moderate |
Same composition (Insulin Glulisine (100IU/ml)), different brands: